[Acetylation polymorphism in lung cancer].
The acetylation phenotype was determined, by means of sulfamethazine measurement, in 87 patients (83 male) with confirmed bronchogenic carcinoma and in 93 healthy control patients (41 male) of equal ages. 48 patients and 54 controls were classified as being "slow acetylators" (Ch2 n.s.) When the persons were individually analysed by phenotype, it was confirmed that the patients showed a significantly lower rate of acetylated sulfamethazine than the control group (p less than 0.02), owing to the poor acetylation of patients with small-cell lung cancer. This difference should be confirmed by more detailed pharmacokinetic studies before regarding it as a possible interference of paraneoplasic type. The polymorphism acetylator cannot be considered a genetic marker related to the risk of having lung cancer.
Laredo Quesada
J M
JM
Departamento de Medicina, Universidad Complutense de Madrid.
Jara Sánchez
C
C
Benítez Rodríguez
J
J
Fernández Gundín
M J
MJ
Vargas Castrillón
E
E
Muñoz González
J J
JJ
Llerena Ruiz
A
A
Cobaleda Polo
J
J
Pérez-Manga
G
G
D000107:Acetylation; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D002283:Carcinoma, Bronchogenic / Q000378:metabolism*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic
D001191:Arylamine N-Acetyltransferase
Polimorfismo acetilador en el cáncer de pulmón.